Therapeutic drug monitoring for triazoles

被引：119

作者：

Hope, William W. ^{[1
]}

Billaud, Eliane M. ^{[2
]}

Lestner, Jodie ^{[1
]}

Denning, David W. ^{[1
]}

机构：

[1] Univ Manchester, Sch Translat Med, Manchester M13 9PT, Lancs, England

[2] Paris Descartes Univ, Hop Europeen G Pompidou, AP HP, Paris, France

来源：

CURRENT OPINION IN INFECTIOUS DISEASES | 2008年 / 21卷 / 06期

关键词：

fluconazole; posaconazole; therapeutic drug monitoring; voriconazole;

D O I：

10.1097/QCO.0b013e3283184611

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Purpose of review Invasive fungal infections are a leading cause of morbidity and mortality in immunocompromised patients, and mechanisms to optimize therapeutic outcomes are urgently required. Therapeutic drug monitoring represents an important component for the routine use of the triazoles. Recent findings Triazoles have revolutionized the prevention and treatment of invasive fungal infections. Increasing data suggest that this class displays important concentration-effect and concentration-toxicity relationships. There has been an increased understanding of the pharmacokinetics and pharmacodynamics of triazoles, and this has facilitated the identification of concentrations (or drug exposures) that are both effective and nontoxic. This review discusses the application of therapeutic drug monitoring to fluconazole, itraconazole, voriconazole and posaconazole. Summary Therapeutic drug monitoring represents an important mechanism to optimize the outcome of immunocompromised patients receiving triazoles.

引用

页码：580 / 586

页数：7

共 63 条

[1] SAFETY, PLASMA-CONCENTRATIONS, AND EFFICACY OF HIGH-DOSE FLUCONAZOLE IN INVASIVE MOLD INFECTIONS [J].

ANAISSIE, EJ ;

KONTOYIANNIS, DP ;

HULS, C ;

VARTIVARIAN, SE ;

KARL, C ;

PRINCE, RA ;

BOSSO, J ;

BODEY, GP .

JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (02) :599-602

[2] Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model [J].

Andes, D ;

van Ogtrop, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2116-2120

[3] In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model [J].

Andes, D ;

Marchillo, K ;

Stamstad, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3165-3169

[4] In vivo pharmacodynamics of a new triazole, ravulconazole, in a murine candidiasis model [J].

Andes, D ;

Marchillo, K ;

Stamstad, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1193-1199

[5] Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis [J].

Andes, D ;

Marchillo, K ;

Conklin, R ;

Krishna, G ;

Ezzet, F ;

Cacciapuoti, A ;

Loebenberg, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :137-142

[6] Association of fluconazole pharmacodynamics with mortality in patients with candidemia [J].

Baddley, John W. ;

Patel, Mukesh ;

Bhavnani, Sujata M. ;

Moser, Stephen A. ;

Andes, David R. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) :3022-3028

[7] FOOD INTERACTION AND STEADY-STATE PHARMACOKINETICS OF ITRACONAZOLE CAPSULES IN HEALTHY MALE-VOLUNTEERS [J].

BARONE, JA ;

KOH, JG ;

BIERMAN, RH ;

COLAIZZI, JL ;

SWANSON, KA ;

GAFFAR, MC ;

MOSKOVITZ, BL ;

MECHLINSKI, W ;

VANDEVELDE, V .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :778-784

[8] ITRACONAZOLE FOR EXPERIMENTAL PULMONARY ASPERGILLOSIS - COMPARISON WITH AMPHOTERICIN-B, INTERACTION WITH CYCLOSPORINE-A, AND CORRELATION BETWEEN THERAPEUTIC RESPONSE AND ITRACONAZOLE CONCENTRATIONS IN PLASMA [J].

BERENGUER, J ;

ALI, NM ;

ALLENDE, MC ;

LEE, J ;

GARRETT, K ;

BATTAGLIA, S ;

PISCITELLI, SC ;

RINALDI, MG ;

PIZZO, PA ;

WALSH, TJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (06) :1303-1308

[9] ANTIFUNGAL PROPHYLAXIS WITH ITRACONAZOLE IN PROLONGED NEUTROPENIA - CORRELATION WITH PLASMA-LEVELS [J].

BOOGAERTS, MA ;

VERHOEF, GE ;

ZACHEE, P ;

DEMUYNCK, H ;

VERBIST, L ;

DEBEULE, K .

MYCOSES, 1989, 32 :103-108

[10] Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy [J].

Boogaerts, MA ;

Maertens, J ;

Van der Geest, R ;

Bosly, A ;

Michaux, JL ;

Van Hoof, A ;

Cleeren, M ;

Wostenborghs, R ;

De Beule, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :981-985

← 1 2 3 4 5 6 7 →